CAMX Stock Overview
Camurus AB (publ), a pharmaceutical company, develops and commercializes pharmaceuticals for serious and chronic conditions in Europe, Australia, the United States, Japan, and internationally.
No risks detected for CAMX from our risk checks.
Price History & Performance
|Historical stock prices|
|Current Share Price||kr159.20|
|52 Week High||kr237.50|
|52 Week Low||kr141.00|
|1 Month Change||-1.36%|
|3 Month Change||-19.52%|
|1 Year Change||-21.77%|
|3 Year Change||62.45%|
|5 Year Change||34.35%|
|Change since IPO||141.21%|
Recent News & Updates
Companies Like Camurus (STO:CAMX) Can Afford To Invest In Growth
Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...
|CAMX||SE Pharmaceuticals||SE Market|
Return vs Industry: CAMX underperformed the Swedish Pharmaceuticals industry which returned -3.4% over the past year.
Return vs Market: CAMX underperformed the Swedish Market which returned 27.1% over the past year.
|CAMX Average Weekly Movement||5.3%|
|Pharmaceuticals Industry Average Movement||7.7%|
|Market Average Movement||6.5%|
|10% most volatile stocks in SE Market||11.9%|
|10% least volatile stocks in SE Market||3.8%|
Stable Share Price: CAMX is not significantly more volatile than the rest of Swedish stocks over the past 3 months, typically moving +/- 5% a week.
Volatility Over Time: CAMX's weekly volatility (5%) has been stable over the past year.
About the Company
Camurus AB (publ), a pharmaceutical company, develops and commercializes pharmaceuticals for serious and chronic conditions in Europe, Australia, the United States, Japan, and internationally. The company offers Buvidal, a buprenorphine injection for the treatment of opioid dependence; and episil oral liquid, a medical device for the treatment of inflammatory and painful conditions in the oral cavity. Its products pipeline also includes Brixadi for opioid dependence; CAM2038 that is in phase III clinical trials for the treatment of chronic pain; CAM2029, which is in phase III clinical trials for the treatment of acromegaly and neuroendocrine tumors; and CAM2043 that is in Phase II clinical trials for treatment of pulmonary arterial hypertension and Raynaud’s phenomenon.
Camurus Fundamentals Summary
|CAMX fundamental statistics|
Is CAMX overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|CAMX income statement (TTM)|
|Cost of Revenue||kr69.67m|
Last Reported Earnings
Sep 30, 2021
Next Earnings Date
Feb 16, 2022
|Earnings per share (EPS)||-2.60|
|Net Profit Margin||-27.11%|
How did CAMX perform over the long term?See historical performance and comparison
Is Camurus undervalued compared to its fair value and its price relative to the market?
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: CAMX (SEK159.2) is trading below our estimate of fair value (SEK955.21)
Significantly Below Fair Value: CAMX is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: CAMX is unprofitable, so we can't compare its PE Ratio to the Swedish Pharmaceuticals industry average.
PE vs Market: CAMX is unprofitable, so we can't compare its PE Ratio to the Swedish market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate CAMX's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: CAMX is overvalued based on its PB Ratio (10.5x) compared to the SE Pharmaceuticals industry average (3.3x).
How is Camurus forecast to perform in the next 1 to 3 years based on estimates from 3 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: CAMX is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (0.3%).
Earnings vs Market: CAMX is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: CAMX's is expected to become profitable in the next 3 years.
Revenue vs Market: CAMX's revenue (34.1% per year) is forecast to grow faster than the Swedish market (5.3% per year).
High Growth Revenue: CAMX's revenue (34.1% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: CAMX's Return on Equity is forecast to be high in 3 years time (25.4%)
How has Camurus performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: CAMX is currently unprofitable.
Growing Profit Margin: CAMX is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: CAMX is unprofitable, and losses have increased over the past 5 years at a rate of 7.6% per year.
Accelerating Growth: Unable to compare CAMX's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: CAMX is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (223.7%).
Return on Equity
High ROE: CAMX has a negative Return on Equity (-17.15%), as it is currently unprofitable.
How is Camurus's financial position?
Financial Position Analysis
Short Term Liabilities: CAMX's short term assets (SEK650.9M) exceed its short term liabilities (SEK197.7M).
Long Term Liabilities: CAMX's short term assets (SEK650.9M) exceed its long term liabilities (SEK20.8M).
Debt to Equity History and Analysis
Debt Level: CAMX is debt free.
Reducing Debt: CAMX has not had any debt for past 5 years.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: CAMX has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: Insufficient data to determine if CAMX has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.
What is Camurus's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate CAMX's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate CAMX's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if CAMX's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if CAMX's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of CAMX's dividend in 3 years as they are not forecast to pay a notable one for the Swedish market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Fredrik Tiberg (58 yo)
Mr. Fredrik Tiberg has been Independent Board Member of Amniotics AB (publ) since 2021. He has been the Chief Executive Officer and President of Camurus AB (publ) since 2003. He is also Head of Research at...
CEO Compensation Analysis
Compensation vs Market: Fredrik's total compensation ($USD1.06M) is above average for companies of similar size in the Swedish market ($USD721.79K).
Compensation vs Earnings: Fredrik's compensation has increased whilst the company is unprofitable.
Experienced Management: CAMX's management team is seasoned and experienced (5.4 years average tenure).
Experienced Board: CAMX's board of directors are considered experienced (3.5 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: CAMX insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Camurus AB (publ)'s employee growth, exchange listings and data sources
- Name: Camurus AB (publ)
- Ticker: CAMX
- Exchange: OM
- Founded: 1991
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Market Cap: kr8.693b
- Shares outstanding: 54.60m
- Website: https://www.camurus.com
Number of Employees
- Camurus AB (publ)
- Ideon Science Park
- Skåne County
- 223 70
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/11/28 18:47|
|End of Day Share Price||2021/11/26 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.